Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats

European Journal of Pharmacology

Volumn 565, Issue 1-3, 2007, Pages 105-112

  Izumi, Takeshi ^a   Iwamoto, Nobuyuki ^a   Kitaichi, Yuji ^a   Kato, Akiko ^a   Inoue, Takeshi ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT syndrome; 5 hydroxytyptamine (5 HT); Antidepressant; Monoamine oxidase (MAO) inhibitor

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; CLORGYLINE; IMIPRAMINE; MIANSERIN; MILNACIPRAN; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SODIUM CHLORIDE;

5 HYDROXYTRYPTAMINE SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; MALE; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL;

5-HYDROXYTRYPTOPHAN; ANIMALS; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DRUG INTERACTIONS; IMIPRAMINE; MALE; MIANSERIN; MONOAMINE OXIDASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN SYNDROME;

EID: 34249048912     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.02.059     Document Type: Article

References (26)

1. Baraban J.M., and Aghajanian G.K. Suppression of firing activity of 5-HT neurons in the dorsal raphe by α-adrenoceptor antagonists. Neuropharmacology 19 (1980) 355-363
2. Berry M.D., Juorio A.V., and Paterson I.A. Possible mechanisms of action of (-) deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog. Neurobiol. 44 (1994) 141-161
3. Cowen P.J., Grahame-Smith D.G., Green A.R., and Heal D.J. β-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioral responses. Br. J. Pharmacol. 76 (1982) 265-270
4. Dresse A., and Scuvee-Moreau J. Influence of the α2-agonist oxaminozoline (S3341) on firing rate of central noradrenergic and serotonergic neurons in the rats. Comparison with clonidine. Arch. Int. Physiol. Biochim. 94 (1986) 99-106
5. Ener R.A., Meglathery S.B., Van Decker W.A., and Gallagher R.M. Serotonin syndrome and other serotonergic disorders. Pain Med. 4 (2003) 63-74
6. Fulton B., and Benfield P. Moclobemide. Drugs 52 (1996) 450-474
7. Izumi T., Iwamoto N., Kitaichi Y., Kato A., Inoue T., and Koyama T. Effect of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats. Eur. J. Pharmacol. 532 (2006) 258-264
8. Jacobs B.L., and Fornal C.A. 5-HT and motor control: a hypothesis. Trends Neurosci. 16 (1993) 346-352
9. Kennedy S.H., McKenna K.F., and Baker G.B. Monoamine oxidase inhibitors. In: Sadock B.J., and Sadock V.A. (Eds). Comprehensive Textbook of Psychiatry. Seventh Edition vol. II (2000), Lippincott Williams & Wilkins, Philadelphia 2397-2407 Chapter 31.20
10. Kennett G.A., Dickinson S.L., and Curzon G. Central serotonergic responses and behavioral adaptation to repeated immobilization: the effect of the corticosterone synthesis inhibitor metyrapone. Eur. J. Pharmacol. 119 (1985) 143-152
11. Lechin F., van der Dijs B., and Hernandez-Adrian G. Dorsal rephe vs. Median raphe serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological and clinical evidences: relevance for neuropharmacological therapy. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30 (2006) 565-585
12. Lucki I., Mitchell S., Nobler S., and Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J. Pharmacol. Exp. Ther. 228 (1984) 133-139
13. Mongeau R., Blier P., and de Montigny C. In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of α2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn-Schmiedeberg's Arch. Pharmacol. 347 (1993) 266-272
14. Mongeau R., Blier P., and de Montigny C. The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res. Rev. 23 (1997) 145-195
15. Numazawa R., Yoshioka M., Matsumoto M., Togashi H., Kemmotsu O., and Saito H. Pharmacological characterization of α2-adrenoceptor regulated serotonin release in the rat hippocampus. Neurosci. Lett. 192 (1995) 161-164
16. Ortmann R., Martin S., Radeke E., and Delini-Stula A. Interaction of β-adrenoceptor agonists with the serotonergic system in rat brain. Abehavioral study using the L-5-HTP syndrome. Naunyn-Schmiedeberg's Arch. Pharmacol. 316 (1981) 225-230
17. Peyron C., Luppi P.H., Fort P., Rampon C., and Jouvet M. Lower brainstem catecholamine afferents to the rat dorsal raphe nucleus. J. Comp. Neurol. 364 (1996) 402-413
18. Pudokina O.L., Cremers T.I.F.H., and Westerink B.H.C. The interaction between the locus coeruleus and dorsal raphe nucleus studied with dural-probe microdialysis. Eur. J. Pharmacol. 445 (2002) 37-42
19. Richard I.H., Kurlan R., and Tanner C. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 48 (1997) 1070-1077
20. Schneider L.S., Tariot P.N., and Goldstein B. Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin. Pharmacol. Ther. 56 (1994) 750-756
21. Siriwardena A., and Kellum Jr. J.M. A 5-HT2 receptor mediates serotonin-induced electrolyte transport in rat left colon. J. Surg. Res. 55 (1993) 323-329
22. 1A selective drugs on the 5-HT behavioral syndrome. Pharmacol. Biochem. Behav. 24 (1986) 1513-1519
23. Sternbach H. The serotonin syndrome. Am. J. Psychiatry 148 (1991) 705-713
24. Sunderland T., Cohen R.M., Molchan S., Lawlor B.A., Mellow A.M., Newhouse P.A., Tariot P.N., Mueller E.A., and Merphy D.L. High-dose selegiline in treatment-resistant older depressive patients. Arch. Gen. Psychiatry 51 (1994) 607-615
25. Thase M.E., and Rush A.J. Treatment-resistant depression. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology, the Fourth Generation of Progress, Chapter 92 (1995), Raven Press, New York 1081-1097
26. White K., and Simpson G. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J. Clin. Psychopharmacol. 5 (1981) 264-282